drugset / Trial / NCT03981211
Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID (injecting related infectious diseases) and commencing inpatient DAA treatment within public hospital services.
Timeline
- Start
- 2021-02-12
- Primary completion
- 2024-12-11
- Completion
- 2025-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glecaprevir/Pibrentasvir | Unknown | 40 mg | Oral |
| Subject | Glecaprevir/Pibrentasvir | Unknown | 100 mg | Oral |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |